Castle Biosciences Inc

CSTL

Add to Watchlist

18.150USD

-0.480-2.58%

Close 05/13, 16:00（ET）Quotes delayed by 15 min

Castle Biosciences Inc's Score

Industry at a Glance

Industry Ranking

14 / 206

Overall Ranking

85 / 4487

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Castle Biosciences Inc Highlights

StrengthsRisks

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 56.62% year-on-year.

Turnaround to Loss

The company's performance has turned to a loss, with the latest annual loss of USD .

Fairly Valued

The company’s latest PE is -43.65, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 27.62M shares, decreasing 6.13% quarter-over-quarter.

Held by Murray Stahl

Star Investor Murray Stahl holds 4.31K shares of this stock.

Analyst Rating

Based on 8 analysts

Strong Buy

Current Rating

47.125

Target Price

+147.51%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Castle Biosciences Inc is 6.87, ranking 104 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 83.68M, representing a year-over-year decrease of 4.90%, while its net profit experienced a year-over-year decrease of 43.82%.

Score

Industry at a Glance

Previous score

6.87

Change

0



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.49

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.97

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.18

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Castle Biosciences Inc is 8.86, ranking 3 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -43.65, which is -456.88% below the recent high of 155.78 and -535.94% above the recent low of -277.59.

Score

Industry at a Glance

Previous score

8.86

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 14/206

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Castle Biosciences Inc is 9.25, ranking 5 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 37.50, with a high of 45.00 and a low of 30.00.

Score

Industry at a Glance

Previous score

9.25

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Castle Biosciences Inc is 6.66, ranking 112 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 23.31 and the support level at 15.40, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.66

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-13

The current institutional shareholding score of Castle Biosciences Inc is 10.00, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 91.06%, representing a quarter-over-quarter decrease of 13.92%. The largest institutional shareholder is James Simons, holding a total of 493.10K shares, representing 1.63% of shares outstanding, with 33.06% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

2.39M

-0.03%

RTW Investments L.P.

2.12M

--

Principal Global Investors (Equity)

1.81M

+0.74%

Portolan Capital Management, L.L.C.

1.73M

+14.15%

Summit Partners Public Asset Management, LLC

1.06M

+164.68%

Dimensional Fund Advisors, L.P.

1.14M

-22.41%

Allianz Global Investors GmbH

597.96K

-3.49%

State Street Investment Management (US)

736.45K

+1.71%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Castle Biosciences Inc is 7.04, ranking 45 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.10. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Castle Biosciences Inc

CSTL

7.93 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.73 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.56 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

LivaNova PLC

LIVN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.35 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bruker Corp

BRKR

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment